Concept Life Sciences Appoints New Group Head of Toxicology
News Oct 12, 2017
Concept Life Sciences (Concept) announced it has appointed Marc Princivalle as Group Head of Toxicology, to support the growth of the Company’s integrated discovery and development services.
In this new role, Marc will lead the group’s toxicology and safety team, driving Concept’s expansion into areas such as de-risking pre-clinical candidate selection, investigation of safety and toxicology in the early stages of small molecule discovery is becoming increasingly important to aid successful downstream development.
Marc has over 16 years’ experience in toxicology, with expertise in peptides, small molecule and monoclonal antibodies for various indications such as diabetes, oncology, urology, gynaecology, infertility and dermatology. Marc also has cross-industry experience, having worked in senior toxicology roles in cosmetics, fragrances, over-the-counter medicines, tobacco products and e-Cigarettes, as well as drug discovery and development. Marc has a PhD in Biochemistry from the Geneva University Hospital in the field of Reproductive Medicine, and is a European Registered Toxicologist.
Paul Doyle, Chief Scientific Officer, Concept Life Sciences, said: “Marc’s appointment brings invaluable expertise and experience to Concept, supporting our mission across the group of delivering knowledge-based and science-led solutions to customers, and bringing safety considerations early into the discovery process. We are delighted to welcome him at an exciting point in the Company’s growth, as we continue to establish Concept Life Sciences as leading experts in integrated discovery and development.”
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE